In July 2021, Blueprint Medicines transferred the responsibilities of booking the U.S. Blueprint Medicines is eligible to receive future milestone fees. In June 2018, the company inked a collaboration contract with CStone Pharmaceuticals to develop and commercialize its three clinical-stage candidates in Mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combo regimes. Sales of the drug grew 30% on a sequential basis and 63.9% on a year-over-year basis.Ĭollaboration revenues were $24.2 million, primarily generated from the agreements with CStone Pharmaceutical and Roche ( RHHBY Quick Quote RHHBY - Free Report). Net product revenues from Ayvakit sales were $39.1 million (including $34.9 million in the United States). Image Source: Zacks Investment Research Quarter in Detailīlueprint Medicines’ total revenues of $63.3 million comprised of net product revenues from Ayvakit (avapritinib) sales and collaboration revenues. The stock has gained 33.4% this year against the industry’s decline of 6.1%. Shares of Blueprint Medicines were up 12.6% on Thursday, following the announcement of the positive results. The company reported total revenues of $62.7 million in the year-ago quarter. Quarterly revenues of $63.3 million also surpassed both the Zacks Consensus Estimate and our estimate of $43 million and $40.7 million, respectively. The company reported a $1.79 per share loss in the year-ago quarter. Blueprint Medicines Corporation ( BPMC Quick Quote BPMC - Free Report) reported a loss of $2.15 per share for the first quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of $2.66 as well as our estimate of a loss of $2.63 per share.
0 Comments
Leave a Reply. |